Carrum, Virta Join Forces on Employer Weight Management Solution
Through a new partnership, Carrum Health can refer patients to Virta Health for weight management support, while Virta can refer patients to Carrum for surgical care.
Walgreens Introduces Virtual Weight Management Offering
Walgreens launched a virtual weight management program offering clinician support and GLP-1 prescriptions for self-pay patients.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
How Employers Can Build an Effective GLP-1 Strategy
Here are five guidelines to help employers balance health outcomes and financial responsibility to ensure that GLP-1 coverage is effective, affordable, and aligned with improved health and workforce well-being for employees and their families.
Priority Health Teams Up with Virta Health for Diabetes, Weight Loss Support
Priority Health has partnered with Virta Health to offer a suite of diabetes and weight management solutions to its employer clients.
The Dangerous Cycle of Anxiety and Diabetes
Effective diabetes management requires a shift from focusing purely on blood sugar levels and weight management medications to embracing the psychological and biological contributors that drive obesity and the disease.
Why Digital Twin Technology Could Help Maximize GLP-1 Efficacy
Digital twin technology can serve as an effective complement to some of the exciting advancements occurring in the metabolic health space, such as new generations of continuous glucose monitors and a slew of GLP-1s, according to Lisa Shah, chief medical officer at Twin Health.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
FTC Seeks More Information on the $16.5B Novo-Catalent Deal, Leading to Another Delay
Novo Holdings’ $16.5 billion planned acquisition of Catalent is facing another delay. Just weeks after Novo decided to resubmit its application to the FTC, the agency is seeking more information about the deal. This move has triggered a second 30-day delay in the antitrust review process.
presented by
How to Help Physicians Generate More Revenue and Make Their Patients Healthier
Interest in using GLP-1 drugs to reduce obesity combined with a desire by physicians to become less dependent on insurance-based reimbursement after the recent Change Healthcare cyberattack is building.
Let’s Make This the Last World Obesity Care Week
By eliminating the term "obesity" in favor of person-centric language, we pave the way for a more equitable healthcare system that prioritizes the well-being of all individuals, regardless of their size or shape.
Omada Expands GLP-1 Care Track To Include Exercise Plans, Member Level Reporting
Omada's newly expanded GLP-1 Care Track provides tailored exercise plans, support for getting off of GLP-1s and calorie tracking. It also offers insight into who is responding to GLP-1s and who is engaging in Omada's program.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
Downside of One-Size-Fits-All: Rethinking Weight-Loss Medications Strategy
A comprehensive approach to obesity management goes beyond prescribing medications for a quick fix.
Lower BMI, Raise ROI: How Physician Practices Can Boost Revenues with Turnkey Weight Management Program
The webinar, scheduled for March 6 at 2pm ET and sponsored by Build My Health, will discuss several topics related to weight management including: an overview of GLP-1 weight loss medication, automation in a subscription-based weight management program, and the rise of provider-to-consumer (PTC) models.
Novo Holdings Bolsters GLP-1 Production Capacity With $16.5B Catalent Buyout
After Novo Holdings acquires Catalent, it will sell three of the contract manufacturing giant’s sites to Novo Nordisk. Those facilities already make Novo Nordisk’s GLP-1 drugs for metabolic conditions, and they will help the company meet projected demand for these products in years to come.
The Prohibitive Economics of Weight Care
How we discuss overweight and obese diagnoses and how we treat those patients is slowly starting to improve. However, there’s still a lot of work to be done – in how we manufacture, market, and manage life-changing weight care medications, as well as how we expand access and improve adherence to them.
WeightWatchers Launches New GLP-1 Support Program
WeightWatchers' new GLP-1 program offers daily nutritional and activity targets, recommended foods, recipes, food and activity tracking, a digital community, virtual workshops and access to coaches 24/7.